Nasolacrimal duct obstruction and acute dacryocystitis associated with infectious mononucleosis (Epstein-Barr virus)
R J
RJ
Steele
D R
DR
Meyer
D002444:Cefuroxime / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002648:Child; D003607:Dacryocystitis / Q000150:complications* / Q000175:diagnosis; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004917:Erythromycin / Q000627:therapeutic use; D015818:Eye Infections, Bacterial / Q000150:complications* / Q000188:drug therapy; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007244:Infectious Mononucleosis / Q000150:complications* / Q000382:microbiology; D007767:Lacrimal Duct Obstruction / Q000150:complications* / Q000175:diagnosis; D008297:Male; D013203:Staphylococcal Infections / Q000150:complications* / Q000188:drug therapy; D013210:Staphylococcus / Q000302:isolation & purification
D002511:Cephalosporins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D004917:Erythromycin; D002444:Cefuroxime